Vaccine-induced antibody responses in patients with carcinoma

Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma

(2009) M Watanabe et al.   BRITISH JOURNAL OF CANCER

Engineered therapeutic antibodies with improved effector functions

(2009) Tsuguo Kubota et al.   CANCER SCIENCE

Cancer/testis (CT) antigens: Potential targets for immunotherapy

(2009) Otavia L. Caballero et al.   CANCER SCIENCE

Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment

(2009) Jaume Capdevila et al.   CANCER TREATMENT REVIEWS

Complement and its role in innate and adaptive immune responses

(2009) Jason R Dunkelberger et al.   CELL RESEARCH

An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy

(2009) Y. Mishima et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial

(2009) I. D. Davis et al.   CLINICAL CANCER RESEARCH

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

(2009) Preeta Tyagi et al.   Clinical Lung Cancer

Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells

(2009) Norberto Zwirner et al.   CURRENT PHARMACEUTICAL DESIGN

Identifying autoantibody signatures in cancer: a promising challenge

(2009) Caroline Desmetz et al.   Expert Review of Proteomics

Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience

(2009) Jianglong Zhu et al.   Expert Review of Vaccines

Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors

(2009) Pravin T.P. Kaumaya et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Monoclonal antibodies for cancer immunotherapy

(2009) Louis M Weiner et al.   LANCET

Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development

(2009) Dana Gancz et al.   MOLECULAR IMMUNOLOGY

Cytokine-secreting follicular T cells shape the antibody repertoire

(2009) R Lee Reinhardt et al.   NATURE IMMUNOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

New insights into the regulation of human B-cell differentiation

(2009) Heike Schmidlin et al.   TRENDS IN IMMUNOLOGY

Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432

(2009) Masatoshi Aoki et al.   VACCINE

Biomarkers for Prostate Cancer

(2008) Danil V. Makarov et al.   Annual Review of Medicine

Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins

(2008) Michael G. Dodds et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma

(2008) Klaus Stensgaard Frederiksen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC)

(2008) María Moreno et al.   CANCER LETTERS

Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities

(2008) A. Natsume et al.   CANCER RESEARCH

Validation of Biomarker-Based Risk Prediction Models

(2008) J. M.G. Taylor et al.   CLINICAL CANCER RESEARCH

Strategies used for MUC1 immunotherapy: human clinical studies

(2008) Choon-Kit Tang et al.   Expert Review of Vaccines

Tumor-specific regulatory T cells in cancer patients

(2008) Sytse J. Piersma et al.   HUMAN IMMUNOLOGY

Multiple roles for CD4+T cells in anti-tumor immune responses

(2008) Richard Kennedy et al.   IMMUNOLOGICAL REVIEWS

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

(2008) Angèle L.M. Oei et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma

(2008) John A. Thompson et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

(2008) D. Atanackovic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit

(2008) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer

(2008) Emile Tan et al.   SURGICAL ONCOLOGY-OXFORD

Advances in Specific Immunotherapy for Prostate Cancer

(2007) Andrea Kiessling et al.   EUROPEAN UROLOGY